News

Biopharma: M&A activity slows
Enlarge image

BusinessSwitzerlandEU

Biopharma: M&A activity slows

19.11.2012 - Big Pharma has spent less money on M&A this year than in 2011, a new report from Deloitte Recap reveals.

Last year, only US$245bn were spent on acquisitions in the life sciences field, according to the analysts from Deloitte Recap LLC. And this year might even get worse: Only US$142bn were invested in this year’s first nine months. The stream of investments has become a feeble trickle – it’s likely that 2012 will end with another drop in the already low M&A sums. Together with similarly shrinking venture capital investments and reduced milestone payments in licensing deals, this adds up to bleak prospects.

Experts hadn’t expected this development. On the contrary, in the wake of the economic crisis, analysts assumed that the number of deals would rise, even though the single acquisition would cost less. But just the opposite says Deloitte Recap's senior biotech analyst Chris Dokomajilar: The industry would be catching its breath, working through the consolidation period while selectively picking off companies that can be easily bagged and bolted on to a big organisation.

Industry is getting increasingly adverse against taking risks. The kind of biotech looking most appealing to buyers at the moment would be a developer with a Phase II asset that's cleared the proof-of-concept hurdle, says Dokomajilar, where the buyer is looking at a significantly de-risked approach to late-stage trial work. This holds true, if you take a look at the five top dealmakers in licensing and joint venture, compiled by FierceBiotech: While leader Roche/Genentech (total deal volume US$1.37bn) closed deals for products in discovery stage or preclinical testing, runners up Abbott (total deal volume: US$1.37bn) and Merck & Co. (total deal volume: US$1.3bn) focused on products in Phase II and Phase III respectively.

According to Dokomajilar, there are some indicators that the situation might improve in the future: "The past few years brought a tremendous amount of liquidity," Dokomajilar told FierceBiotech, counting US$215b in "committed" dollars, upfront and equity payments offering investors a chance to cash out. Many of those investor groups are required to reinvest a portion of their cash in this industry. This means that a lot of that money should be flowing back in. That, however, still hasn’t happened yet.

© eurobiotechnews.eu/bk

http://www.european-biotechnology-news.com/news/news/2012-04/biopharma-ma-activity-slows.html

FinancingSwitzerlandEU

29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.

Industry reportGermany

27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).

Clinical ResearchFrancePortugal

21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.

Immuno-oncologyNetherlandsBelgium

21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.

RegulatorySwitzerlandEU

20.04.2016 The US government is forking out up to US$100m to get Basilea Pharmaceutica’s broad-spectrum antibiotic ceftobiprole on the US market. In the EU, ceftobiprole is already available.

Immuno-oncologyUK

19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.

FinancingSwitzerlandFranceEUGermanyDenmark

15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.

Event ReviewSwitzerlandBelgiumEU

13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.

FinancingGermanyNetherlandsEU

12.04.2016 German-Dutch life science investment specialist Forbion Capital Partners has raised more than €180m for its venture capital fund Forbion Capital Fund III. Once more the money will primarily go to European start-ups.

Event ReviewGermanyEU

08.04.2016 Do you win by being innovative?, was the question asked at this year’s DIA Euromeeting in Hamburg. In a relaxed and cooperative atmosphere, regulators, physicians and patients had ample opportunity to interact with the healthcare industry.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

München

BioVaria 2016

Berlin (GER)

XIV. BIONNALE 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • FORMYCON (D)24.56 EUR5.59%

FLOP

  • SERODUS (N)1.46 NOK-14.12%
  • PHOTOCURE (N)39.50 NOK-7.49%
  • BIONOR PHARMA (N)0.79 NOK-7.06%

TOP

  • AB SCIENCE (F)18.84 EUR71.3%
  • SYNAIRGEN (UK)35.75 GBP45.9%
  • BIOFRONTERA (D)3.17 EUR36.1%

FLOP

  • SERODUS (N)1.46 NOK-28.8%
  • THERAMETRICS (CH)0.03 CHF-25.0%
  • OREXO (S)50.00 SEK-19.4%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)31.20 SEK2022.4%
  • NICOX (F)8.55 EUR352.4%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)6.10 SEK-88.0%
  • BB BIOTECH (D)46.44 EUR-82.3%
  • BIOTEST (D)16.69 EUR-76.5%

No liability assumed, Date: 01.05.2016